Showing 6411-6420 of 9528 results for "".
- TNF Blockers Are Not Associated With Poor Pregnancy Outcomeshttps://practicaldermatology.com/news/tnf-blockers-are-not-associated-with-poor-pregnancy-outcomes/2462122/Continuing tumor necrosis factor (TNF) inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy, according to research presented at ACR Convergence 2023, the American College of Rheumatology&r
- ACR: TREMFYA Improves Pain, Physical Function and Fatigue in PsA Patients Through Six Monthshttps://practicaldermatology.com/news/acr-tremfya-improves-pain-physical-function-and-fatigue-in-psa-patients-through-six-months/2462121/Substantial numbers of people living with treatment-resistant active PsA who used TREMFYA (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months, according to new data from the CorEvitas Psoriatic Arthritis (PsA) and Spo
- Biosimilar News: FDA Approves Stelara Biosimilar Wezlanahttps://practicaldermatology.com/news/biosimilar-news-fda-approves-stelara-biosimilar-wezlana/2462118/The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Stelara (ustekinumab) for psoriasis and multiple other inflammatory diseases. The FDA granted the approval of Wezlana to Amgen, Inc. Wezlana, like Stelar
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- Survey: Americans with Mild-to-Moderate Acne Have Defeatist Attitudes About Treatment, Despite Self-Consciousnesshttps://practicaldermatology.com/news/sun-pharma-survey-reveals-americans-with-mild-to-moderate-acne-have-defeatist-attitudes-about-treatment-despite-self-consciousness/2462110/A new survey reveals defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness. Among the 1,003 survey respondents ages 13-55, only three in 10 reported having seen a dermatologist, suggesting that many people with mild-to-moderate acne ar
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Almirall Highlights World Psoriasis Day With the Nina Serieshttps://practicaldermatology.com/news/world-psoriasis-day/2462102/October 29, 2023 is World Psoriasis Day, and Almirall is highlighting the impact of this disease on the wellbeing of individuals, their families, and friends through the series Nina, and with the support of the International Federation of Psoriasis Associations. Nina
- Biosimilar News: YUFLYMA Added to CarePartners Specialty Pharmacy Cost Savings Programshttps://practicaldermatology.com/news/biosimilar-news-yuflyma-added-to-carepartners-specialty-pharmacy-cost-savings-programs/2462100/Celltrion USA, Inc.’s US Food and Drug Administration-approved biosimilar, YUFLYMA (adalimumab-aaty) has been added to CarePartners Specialty Pharmacy Cost Savings Programs. YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira (adal
- Study: Dupilumab Shows Acceptable Long-term Safety Profile for ADhttps://practicaldermatology.com/news/study-dupilumab-shows-acceptable-safety-profile/2462097/Results from a five-year analysis suggested that long-term dupilumab for the treatment of moderate-to-severe atopic dermatitis (AD) in adults is safe and consistent with other placebo-controlled trials.
- UCSF's HS PROGRESS Aims to Shed Light on Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucsfs-hs-progress-aims-to-shed-light-on-hidradenitis-suppurativa/2462092/University of California-San Francisco (UCSF) is leading HS PROGRESS (Hidradenitis Suppurativa [HS] Prospective Observational Registry and bioSpecimen repoSitory), a multicenter, longitudinal study that aims to comprehensively characterize HS from clinical and biological perspectives. <